靶向治疗背景下非小细胞肺癌传统化疗的地位与发展

[1] Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial[J] . Edward B Garon,Tudor-Eliade Ciuleanu,Oscar Arrieta,Kumar Prabhash,Konstantinos N Syrigos,Tuncay Goksel,Keunchil Park,Vera Gorbunova,Ruben Dario Kowalyszyn,Joanna Pikiel,Grzegorz Czyzewicz,Sergey V Orlov,Conrad R Lewanski,Michael Thomas,Paolo Bidoli,Shaker Da

[2] Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study[J] . Glenwood D. Goss,Chris O’Callaghan,Ian Lorimer,Ming-Sound Tsao,Gregory A. Masters,James Jett,Martin J. Edelman,Rogerio Lilenbaum,Hak Choy,Fadlo Khuri,Katherine Pisters,David Gandara,Kemp Kernstine,Charles Butts,Jonathan Noble,Thomas A. Hensing,Kendrith Rowland,Joan Schiller,Keyue Ding,Frances A. Shepherd.Journal of Clinical Oncology . 2013 (27)

[3] Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial[J] . Yi-Long Wu,Jin Soo Lee,Sumitra Thongprasert,Chong-Jen Yu,Li Zhang,Guia Ladrera,Vichien Srimuninnimit,Virote Sriuranpong,Jennifer Sandoval-Tan,Yunzhong Zhu,Meilin Liao,Caicun Zhou,Hongming Pan,Victor Lee,Yuh-Min Chen,Yan Sun,Benjamin Margono,Fatima Fuerte,Gee-Chen Chang,Kasan Seetalarom,Jie Wang,Ashley Cheng,Elisna Syahruddin,Xiaopin

[4] Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study[J] . Thomas J. Lynch,Igor Bondarenko,Alexander Luft,Piotr Serwatowski,Fabrice Barlesi,Raju Chacko,Martin Sebastian,Joel Neal,Haolan Lu,Jean-Marie Cuillerot,Martin Reck.Journal of Clinical Oncology . 2012 (17)

[5] Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial[J] . Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Michael Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,Eckart Laack,Martin Reck,Jesús Corral,Symantha Melemed,William John,Nadia Chouaki,Annamari

[6] Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J] . Caicun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiao-Qing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jianan Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You.Lancet Oncology . 2011 (8)

[7] Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial[J] . Journal of Thoracic Oncology . 2010 (9)

[8] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study[J] . Tudor Ciuleanu,Thomas Brodowicz,Christoph Zielinski,Joo Hang Kim,Maciej Krzakowski,Eckart Laack,Yi-Long Wu,Isabel Bover,Stephen Begbie,Valentina Tzekova,Branka Cucevic,Jose Rodrigues Pereira,Sung Hyun Yang,Jayaprakash Madhavan,Katherine P Sugarman,Patrick Peterson,William J John,Kurt Krejcy,Chandra P Belani.The Lancet . 2009 (969

[9] ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (10) : 902 - 906

[10] Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial[J] . Thomas Brodowicz,Maciej Krzakowski,Matjaz Zwitter,Valentina Tzekova,Rodryg Ramlau,Nicolae Ghilezan,Tudor Ciuleanu,Branka Cucevic,Kalman Gyurkovits,Ernst Ulsperger,Jacek Jassem,Mislav Grgic,Pinar Saip,Maria Szilasi,Christoph Wiltschke,Maria Wagnerova,Natalya Oskina,Victoria Soldatenkova,Christoph Zielinski,Miklos Wenczl.Lung C

[1] Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial[J] . Edward B Garon,Tudor-Eliade Ciuleanu,Oscar Arrieta,Kumar Prabhash,Konstantinos N Syrigos,Tuncay Goksel,Keunchil Park,Vera Gorbunova,Ruben Dario Kowalyszyn,Joanna Pikiel,Grzegorz Czyzewicz,Sergey V Orlov,Conrad R Lewanski,Michael Thomas,Paolo Bidoli,Shaker Da

[2] Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study[J] . Glenwood D. Goss,Chris O’Callaghan,Ian Lorimer,Ming-Sound Tsao,Gregory A. Masters,James Jett,Martin J. Edelman,Rogerio Lilenbaum,Hak Choy,Fadlo Khuri,Katherine Pisters,David Gandara,Kemp Kernstine,Charles Butts,Jonathan Noble,Thomas A. Hensing,Kendrith Rowland,Joan Schiller,Keyue Ding,Frances A. Shepherd.Journal of Clinical Oncology . 2013 (27)

[3] Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial[J] . Yi-Long Wu,Jin Soo Lee,Sumitra Thongprasert,Chong-Jen Yu,Li Zhang,Guia Ladrera,Vichien Srimuninnimit,Virote Sriuranpong,Jennifer Sandoval-Tan,Yunzhong Zhu,Meilin Liao,Caicun Zhou,Hongming Pan,Victor Lee,Yuh-Min Chen,Yan Sun,Benjamin Margono,Fatima Fuerte,Gee-Chen Chang,Kasan Seetalarom,Jie Wang,Ashley Cheng,Elisna Syahruddin,Xiaopin

[4] Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study[J] . Thomas J. Lynch,Igor Bondarenko,Alexander Luft,Piotr Serwatowski,Fabrice Barlesi,Raju Chacko,Martin Sebastian,Joel Neal,Haolan Lu,Jean-Marie Cuillerot,Martin Reck.Journal of Clinical Oncology . 2012 (17)

[5] Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial[J] . Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Michael Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,Eckart Laack,Martin Reck,Jesús Corral,Symantha Melemed,William John,Nadia Chouaki,Annamari

[6] Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J] . Caicun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiao-Qing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jianan Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You.Lancet Oncology . 2011 (8)

[7] Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial[J] . Journal of Thoracic Oncology . 2010 (9)

[8] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study[J] . Tudor Ciuleanu,Thomas Brodowicz,Christoph Zielinski,Joo Hang Kim,Maciej Krzakowski,Eckart Laack,Yi-Long Wu,Isabel Bover,Stephen Begbie,Valentina Tzekova,Branka Cucevic,Jose Rodrigues Pereira,Sung Hyun Yang,Jayaprakash Madhavan,Katherine P Sugarman,Patrick Peterson,William J John,Kurt Krejcy,Chandra P Belani.The Lancet . 2009 (969

[9] ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (10) : 902 - 906

[10] Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial[J] . Thomas Brodowicz,Maciej Krzakowski,Matjaz Zwitter,Valentina Tzekova,Rodryg Ramlau,Nicolae Ghilezan,Tudor Ciuleanu,Branka Cucevic,Kalman Gyurkovits,Ernst Ulsperger,Jacek Jassem,Mislav Grgic,Pinar Saip,Maria Szilasi,Christoph Wiltschke,Maria Wagnerova,Natalya Oskina,Victoria Soldatenkova,Christoph Zielinski,Miklos Wenczl.Lung C